Hematemesis News and Research

RSS

Does COVID-19 increase the risk of future gastrointestinal disorders?

Scientists review existing literature to examine the association between acute COVID-19 and the incidence of gastrointestinal symptoms.

2 Aug 2023

FDA authorizes first device to treat patients with walled-off pancreatic necrosis

Today, the U.S. Food and Drug Administration authorized marketing of the EndoRotor System to resect (cut out) and remove necrotic (dead) tissue for patients with walled-off pancreatic necrosis (WOPN), a potentially deadly condition which can occur several weeks after an episode of severe acute pancreatitis, often requiring tissue removal.

23 Dec 2020

Treating hospitalized COVID-19 patients with anticoagulants may improve their survival chances

Treating hospitalized COVID-19 patients with anticoagulants-;blood thinners that slow down clotting-;may improve their chances of survival, researchers from the Mount Sinai COVID Informatics Center report.

7 May 2020

Researchers identify unique bleeding syndrome linked to cirrhosis and portal hypertension

A unique bleeding syndrome associated with cirrhosis and portal hypertension has been identified by researchers at the Medical University of South Carolina, Wake Forest University Medical Center, and the University of Texas Southwestern Medical Center in an article published online on April 21, 2017 by the Journal of Investigative Medicine.

21 Apr 2017

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Exelixis, Inc. today reported preliminary data from an ongoing phase 1 dose escalation study of cabozantinib in Japan.

1 Oct 2012

Underlying malignancies can cause rebleeding after negative angiography

Acute non-variceal gastrointestinal bleeding accounts for approximately 20% of emergency room visits and 5% of admissions. Although endoscopy has been used as a first-line treatment option in patients with gastrointestinal bleeding, angiographic intervention can be used as a safe diagnostic and treatment method in patients with gastrointestinal bleeding that is refractory to endoscopic treatment.

17 Sep 2009

Cause and clinical outcome of portal vein thrombosis

Among the 118 patients with portal vein thrombosis, noncirrhotic and nontumoral extrahepatic portal vein obstruction are young and present with well tolerated bleed.

15 Oct 2007